Imaging of Islet Transplantation With PET and MRT
|ClinicalTrials.gov Identifier: NCT00417131|
Recruitment Status : Completed
First Posted : December 29, 2006
Last Update Posted : August 4, 2011
|Condition or disease|
|Islet Transplantation Diabetes Type 1|
It is suspected that the current need for repeated islets transplantation to treat diabetes type I is dependent on an early destruction of the islets when infused into the portal vein.
To trace the fate of the islet at and after infusion into the portal vein.
Islets are labelled in vitro with a radioactive tracer that can be measured with positron emission tomography. 10-20 percent of the graft is labelled. Just prior to start of infusion labelled islets are mixed with unlabelled islets (80-90 percent of the graft). The tracer used is FDG and stands for 2-[18F]-2-deoxy-D-glucose. At infusion the patient is placed in the combined computer tomography and PET camera to follow the infusion. The imaging is almost continuous for 2 h at and after infusion.
Calculations of proportion of surviving islets and rate of destruction. Localisation and distribution of islets in the liver of the recipient.
|Study Type :||Observational|
|Actual Enrollment :||8 participants|
|Official Title:||Imaging of Islet Transplantation With PET and MRT|
|Study Start Date :||October 2006|
|Primary Completion Date :||November 2010|
|Study Completion Date :||November 2010|
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00417131
|Karolinska University Hospital, Dept. of Transplantation surgery|
|Stockholm, Sweden, S-141 86|
|Uppsala University Hospital, Dept of Transplantation Surgery|
|Uppsala, Sweden, S-751 85|
|Principal Investigator:||Gunnar Tufveson, Professor||Dept of Transplantation, Uppsala University Hospital|